We identified a previously undocumented mutation in the dihydropteroate synthase (folP) gene associated with Neisseria meningitidis sulfonamide resistance. A PCR-based assay to detect this mutation, which is 100% predictive of sulfonamide resistance, was developed.
reduction or an artifact due to the decline in the proportion of culture-proven cases of disease. In 2002, 61.1% of cases were diagnosed by specific meningococcal PCR only, and with fewer isolates available for testing, valuable information relating to sulfonamide susceptibility is being lost.
In this study, we examined the diversity of folP genes in N. meningitidis to assess the potential for development of a PCRbased protocol to detect resistance. Following alignment of the DNA sequences of folP genes from nine unrelated N. meningitidis strains (four sensitive and five resistant) of serogroups A, B, and C (9, 15) , four single-base-pair differences (in addition to those already documented) were identified. At nucleotide position 261, A is present in sensitive determinants, whereas G is present in resistant determinants (G261). The other three differences included changes from G to A at position 451 (A451), C to A at position 682 (A682), and either C or G to T at position 751 (T751). In order to verify whether these changes were also seen in Irish clinical isolates, we sequenced two independently derived PCR products of the entire coding region of the folP genes from nine clinical isolates and the resistant serogroup B reference strain, H44/76. Five of the nine isolates were resistant (sulfadiazine MICs of 10, 20, 50, 100, and 200 g/ml), and four were sensitive (sulfadiazine MICS of 0.4, 0.8, 3.2, and 6.4 g/ml).
The sequence of the folP gene from the H44/76 reference strain was identical to that of MO035 (GenBank accession no. X68062) (15) . Three of the five sulfadiazine-resistant clinical isolates contained a sequence coding for leucine at position 31, and the other two contained an additional 6-bp insertion sequence-mechanisms previously documented to confer resistance. Only two isolates contained the G261 alteration, three contained the A451 alteration, none harbored the T751 alteration, and all five contained the A682 alteration. None of the four sensitive determinants contained any of these alterations or any of the mutations previously documented to confer resistance. Alignment of the 19 sequences demonstrated that only the A682 alteration was common to the sequences of the resistant determinants irrespective of the sulfadiazine MICs for them. Consequently, we developed an assay to detect this alteration by PCR amplification followed by restriction endonuclease digestion.
We designed primers for PCR analysis to create or delete restriction sites so that this polymorphism, which is not described by a natural unique restriction site, could be detected. In resistant determinants with the A at position 682, a single base change at position 691 generates an AluI site, and therefore the A-to-C transition in sensitive determinants removes the AluI site. To detect this transition, two primers were designed that were specific for the regions flanking position 682 to yield a 120-bp amplicon ( Table 1 ). The downstream primer contained a mismatch to generate an AluI site in resistant determinants and a mismatch to delete an existing AluI site. The upstream primer contained two substitutions (at positions 610 and 611) to generate an artificial AluI site in all amplicons regardless of the nature of the determinant. Thus, the presence or absence of the 120-bp band (undigested amplicon) serves as an indicator of whether digestion of PCR products with AluI is complete or not. After complete digestion, the sensitive determinant is 95 bp and the resistant determinant is 71 bp. We applied this assay to strain H44/76 and the nine clinical isolates. A 71-bp product was observed after digestion with the five resistant isolates and in strain H44/76, correctly identifying A682 in each of these, while a 95-bp product was observed with each of the four sensitive isolates, indicating that these did not contain A682. To confirm that A682 was consistent among all resistant determinants, we assayed a further 10 clinical isolates for which sulfadiazine MICs were Ն10 g/ml. Each yielded a 71-bp product, indicating the presence of A682 in their folP genes, correctly identifying them as resistant. These results indicated that the A682 transition, predicting the codon alteration Arg228-Ser, is present in the folP genes of all sulfadiazine-resistant isolates examined. The exact influence of this nucleotide substitution is unknown, especially given the findings of previous studies (8, 9, 14) . It is possible that as a consequence of the C-to-A transition resulting in Arg228-Ser, resistance could be acquired in N. meningitidis as has been reported in Streptococcus pyogenes (11) . A change of residue in the corresponding position, 213, in the DHPS determinant of S. pyogenes from arginine (susceptible strain) to glycine (resistant strain) had a major effect on sulfonamide susceptibility (11) . Site-directed mutagenesis and enzyme kinetic studies demonstrated that resistance was almost reversible by changing only that position (11). Jonsson et al. concluded that this single Arg213-Gly change resulting from a point mutation led to significant sulfonamide resistance in S. pyogenes (11) .
In addition, by inference from structure-based DHPS sequence alignments from Escherichia coli (2), Staphylococcus aureus (10) , and Mycobacterium tuberculosis (6), Arg-228 lies in the loop 7Ј region of the DHPS molecule; this region is highly conserved and is involved in substrate binding. The preceding residue, lysine 227, is absolutely conserved and is involved in binding the substrate 6-hydroxymethyl-7,8-dihydropterin pyrophosphate; arginine 228 is very highly conserved and believed to be involved in binding the substrate para-aminobenzoic acid, although the exact mechanism of binding remains to be elucidated (6) . Therefore, it is not surprising that a change in residue 228 affects susceptibility.
The systems described here-in particular the A682 PCRrestriction fragment length polymorphism assay-can be used to identify folP genotypes to distinguish between susceptible and resistant strains with 100% predictability. The methodology of PCR followed by restriction analysis can be used to develop similar tests for any other novel base pair transitions identified. Although the restriction digestion step is the limiting step, we have included an additional restriction site as an internal control to ensure against misinterpretations due to incomplete digestion. This is the first description detailing an association between this alteration and meningococcal sulfonamide insensitivity and the first description of a PCR-based detection assay that can rapidly, reliably, and accurately predict sulfonamide resistance in meningococci.
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